[CROI 2012] Programma e attese

[Dora]

Vorrei ricordarvi che domani esce il programma del CROI 2012, che si terrà a Seattle dal 5 all'8 marzo prossimi.

Per le edizioni degli anni passati e le relative discussioni, vi rimando a CROI (Conferenze sui Retrovirus e le Infezioni Opportunistiche).

[uffa2]

5 marzo
09-14: Program Committee Workshop for New Investigators and Trainees featuring the Martin Delaney Lecture: Community Responses to PrEP and Treatment as Prevention, Nikos Dedes
14.30-16.30: Frontiers in Laboratory Science Workshop, Clinical Trials Design Workshop
17th Bernard Fields Award Lecture: Defying the Structure and Variability of HIV with Broadly Neutralizing Antibodies, Dennis Burton
17.00-19.00: 6th N’Galy-Mann Award Lecture: CAPRISA: Partnering for Scientific Innovation in HIV Prevention and Treatment, Quarraisha and Salim Abdool Karim
6 marzo
8.30-9.00 ART for Prevention: The Science and the Art, Wafaa El-Sadr
9.00-9.30 am Arms and the Virus: Evolution of HIV, SIV, and their Hosts, Michael Emerman
10.00-12.00 Oral Abstracts
Critical Treatment Issues in Women and Children
HIV Prevention: PrEP, Microbicides, and Circumcision
HIV-Host Interplay: The Immune and Cellular Response
Breakthroughs in Hepatitis
13.00-14.00 Themed Discussions
Biomarkers of Inflammation in Pregnant and Nonpregnant Women
Complications of HIV and ART in Children and Adolescents
Pharmocogenomics of Drug Toxicity
Restriction Factors and Virus-Host Coevolution
Cryptococcal Meningitis: Advances in Diagnosis and Management
Predicting Hepatitis C Treatment Responses
14.00-16.00 Poster Abstracts
Cellular Factors in Viral Replication and Novel Therapeutic Targets
New Tools for Analysis of Viral Replication
Impact of GBV and HSV on HIV
HIV-Macrophage Interplay
Viral Characteristics Linked to Pathogenecity
Immune Activation: Contributing Factors and Impact on Progression
Viral Persistence on Therapy
Viral Replication off Therapy
Coordinated Immune Responses
Factors Associated with HIV Resistance
Correlates of Risk in RV144 and Related Trials
Post-Hoc Assessment of Vaccine Trials
Neuropathogenesis Virology: HIV and SIV
Neuropathogenesis: Early Infection Markers, CNS Inflammation
Phylogeny and Relationship to Transmission, Pathogenicity and HLA Profile
Genetics and Phylogenetics of HIV Transmission
Compartment and Sanctuary Site Pharmacology
Pharmacometrics: Drug Exposure and Response Modeling
HIV Diagnostics: Nucleic Acid Detection, Sequencing and Dried Blood Spots
Mechanisms of Antiviral Drug Resistance
Resistance to 2nd Generation NNRTIs
HCV Epidemiology and Natural History
Cure of a Chronic Viral Infection
Genes and Drugs: Pharmacogenetics of HCV Treatment
Biomarkers and Complications: Associations and ART Effects
Inflammatory Biomarkers, Immune Activation and ART
Abacavir and Inflammation
Fat: Changes on ART and Pathogenesis
Dyslipidemia
Glucose, Insulin Resistance and Testosterone
Strategies for TB Screening: Prevention, Diagnosis and Reduced Transmission
TB Diagnostics
ART Strategies and Outcomes among Children
Cardiovascular Complications in Children and Adolescents
Response to Protective Vaccines
Host and Immune Factors in Pediatric HIV Infection
PMTCT: Retention in Care and Adherence during and after Pregnancy
Point of Care: CD4 in Pregnancy
PMTCT: Infant Feeding Recommendations and Practices
Complexities of ART for Pregnant and Postpartum Women
ART Immune Status and Viral Suppression during Pregnancy
Women and HIV: Access to Care and Sexual Power Dynamics
HIV Prevention Trials: HIV Test Performance, Pregnancy, Bone Toxicity and Resistance
Preclinical Studies of Microbicides
Animal and Human Studies of PrEP and Vaginal Rings
Risk Behaviors
Transmission Networks
Linkage, Adherence, and Retention in Care
16.00-16.30 Oral Abstracts
Host and Viral Factors in HIV Transmission
16.30-18.00 Symposia
Host Cell Factors InfluencingHIV Replication
Next Steps in Using ARVsfor Prevention
Hepatitis: Discovery in Practice
7 marzo
8:30-9 am Elimination of Mother-to-Child Transmission of HIV, Dorothy Mbori-Ngacha
9-9:30 am Structure and Function of the HIV-1 Envelope Glycoproteins, Joseph Sodroski
10.00-12.00 Oral Abstracts
Neurological Issues in HIV Infection: Natural History, Markers, and Treatment
Treatment in Resource Limited Settings: Impact and Challenges
Advances in Vaccines and IBTs
State of the “ART” and Drug Resistance
13.00-14.00 Themed Discussions
Aging and Neurocognitive Impairment
Elite Controllers
Novel Approaches to Testing and Linkage to Care
Pharmacometrics: Drug Exposure and Response Modelling
Correlates of Risk in RV144 and Related Trials
Animal and Human Studies of PrEP and Vaginal Rings
14.00-16.00 Poster Abstracts
Envelope, Receptors and Virus Binding to Target Cells, Autophagy
Restriction Factors and Virus-Host Co-Evolution
Host Resistance to Infection and Disease Progression
Impact of HIV on Immune Cell Function and Reservoir Studies
HIV and T Cell Exhaustion
Unconventional Reservoirs
Breaking Latency
CTL Escape Pathways
CTL and Viral Control in vivo
CTL and Viral Suppression in vitro
Novel Vaccine Strategies
Novel Gene Therapy Approaches
HAND Predictors and Comorbidities
HIV-associated Neuropathies
HAND Therapies and CNS Penetration
Molecular Epidemiology: Primate Viruses and How They Affect Humans
Acute/Primary HIV Infection
HIV Diagnostics: Acute and Recent Infection
New ARV Agents and Approaches
Pharmacokinetics, Dynamics, Adverse Reactions and Complications
ART: Inititation and Outcomes
Treatment Initiation
Improving Treatment Outcome
HIV Diagnostics: Point of Care and Mobile CD4 Testing
Transmitted ARV Drug Resistance in Developed Countries
Prevalence of Darunavir Resistance in Developing Countries
Predicting Hepatitis C Treatment Responses
The Next Frontier: HCV Resistance
ART, Insulin Resistance, and the Liver
Cardiovascular and Pulmonary Disease: Risk Factors and Predictors of Progression
Stroke, Myocardial Infarction and Sudden Death Role of HIV
Interventions to Reduce Cardiovascular Disease
Sexually Transmitted Infections and Dysplasia
HIV-associated Malignancies: Emerging Themes in Epidemiology
HIV-associated Malignancies: Update in Treatment and Pathogenesis
TB Risk, Outcomes and Impact of ART on TB Treatment
TB Drug Resistance
Immune Reconstitution Inflammatory Sydromes and Pathogenic Specific Immunity
Early Infant HIV Diagnosis
Retention and Adherence in Children and Adolescents
Treatment Outcomes and Complications in HIV+ Adolescents
ARV Pharmacokinetics and Pharmacogenetics in Children
Estimates of New Pediatric Infections and PMTCT Program Outcomes
Pregnancy Complications among HIV+ Women
PMTCT: Child Health Outcomes
Long Term Outcomes of ART Exposure for PMTCT
Biomarkers of Inflammation in Pregnant and Non-Pregnant Women
Estimating Incidence
Engagement in Care
Community Viral Load
Disease Progression and Mortality
16.00-16.30 Oral Abstracts
Metabolic and Cardiovascular Complications
16.30-18.00 Symposia
Pathways toward a Cure: Viral Latency and Reservoirs
Recognizing Risk in HIV-Exposed and Infected Infants
New Frontiers in HIV Testing
8 marzo
8.30-09.00 From the Cage to the Clinic: Developing TB Regimens for the Next 40 Years, Eric Nuermberger
09.00-9.30 AIDS and the Global Burden of Disease, Christopher Murray
10.00 -12.00 Oral Abstracts
Cancer and HIV: Treatment, Pathogenesis, and Risk Factors
Epidemiology: Lives Saved and Persons at Risk
TB and Vaccine Preventable Diseases
HIV Persistence, Latency, and Eradication
16.00-14.00 Themed Discussions
Molecular Epidemiology: Primate Viruses and How They Affect Humans
HIV-associated Malignancies: Emerging Themes in Epidemiology
Complexities of ART for Pregnant and Postpartum Women
TB Diagnostics
Biomarkers and Complications: Associations and ART Effects
Breaking Latency
14.00-16.00 Poster Abstracts
Antiviral Restrictions: Insight into Mechanisms of Action
Studies on Viral Capsid and Assembly
Virus Evolution, Fitness and Splicing
Studies on Antigen Presenting Cell Changes in HIV Infection
Impact of Treatment on Different Cell Subsets
Elite Controllers
HIV Reservoir: Immunologic Markers and Interventions
in vitro Models of Latency
Evolution of the Neutralizing Antibody Response in vivo
Novel Methods for Detecting and Evaluating Neutralizing Antibodies
Neutralizing Antibodies: Application to Vaccines and Therapies
Therapeutic Vaccines and Immune Based Therapies
Aging and Neurocognitive Impairment
Clinical Evaluation of Neurocognitive and Neuropsychiatric Dysfunction
Neuroimaging Studies of HAND
Methods for Phylogenetic and Population Analysis of HIV
Mechanism of Genital HIV Transmission
Pharmacogenomics of Drug Toxicity
Drug Interactions
ART: Randomized Trials
Disparities and Linkage to Care
Plasma HIV RNA in HIV-1 and HIV-2 Infection
Drug Resistance Evolution
Resistance to Entry Inhibitors
ARV Resistance and Therapy Outcome
Immunopathogenesis of Hepatitis
Hepatitis B and E around the World
Frailty and Muscle Mass: Measures, Predictors and Outcomes
Estimating Creatinine Clearance: Are We There Yet?
Renal Disease: Association with Long Term Outcomes
Low Bone Density: Etiology, Associations and Role of ART
Vitamin D Deficiency: Let the Sun Shine In
Hepatic and Gastrointestinal Complications
Bacterial and Non-Tuberculosis Mycobacterial Infections
Cryptococcal Meningitis: Advances in Diagnosis and Management
Response to ART and Comorbidities in Infants and Children
Complication of HIV and ART in Children and Adolescents
HIV Drug Resistance and Tropism (after Treatment Failure) in Children
TB Diagnosis and Treatment in Children
ARV Regimens and Prevention of MTCT
ART Pharmacokinetics during Pregnancy
Neutralizing Antibodies and MTCT
Immune Factors Associated with Immune Activation and MTCT
Women and HIV: Structural Factors, Contraceptives and Mucosal Integrity
HIV Prevention: PrEP, Circumcision and Population Viral Load
Modelling the Impact of Prevention Strategies
Novel Approaches to Testing and Linkage to Care
Testing and Prevention
HIV Testing and Disclosure
16.00-16.30 Oral Abstracts
HIV/SIV Host Interactions
16.30-18.00 Symposia
Ontogeny of a Protective Immune Response to HIV
Scientific Advances in TB Pathogenesis and Treatment
The Long and Winding Road of HIV Complications

qui il PDF: http://www.retroconference.org/static/i ... glance.pdf

[Dora]

Finalmente si sono decisi a pubblicare il programma completo. Lo trovate qui:

CROI 2012 - 19th Conference on Retroviruses and Opportunistic Infections - Pocket Program


Appena possibile, segnalerò le relazioni che mi interessano di più e che spero di riuscire a seguire. Poi, con calma, magari anche i poster.

[HLAB5701]

Phylogeny and Relationship to Transmission, Pathogenicity and HLA Profile

questo sembra interessante!!

[thelondonsuede]

SI PREANNUNCIA UN CROI INTERESSANTE COME UNA PIANTA GRASSA

[uffa2]

London, non mettere il dito nella piaga: quest’anno sono riuscito ad ammazzare pure le piante grasse, mi sa

[skydrake]

SI PREANNUNCIA UN CROI INTERESSANTE COME UNA PIANTA GRASSA

Colleziono piante grasse!

London, non mettere il dito nella piaga: quest’anno sono riuscito ad ammazzare pure le piante grasse, mi sa

Possibile????? Eppure sono considerate piante medio facili!!!!

Forse a te serve una pianta facilissima, tipo una Saintpaulia Confusa
http://www.gesneriads.ca/saintp18.htm



Tornando in topic, vi sono comunque alcune cose interessanti:

Predicting Hepatitis C Treatment Responses
HIV-Macrophage Interplay
Viral Persistence on Therapy
Viral Replication off Therapy
Factors Associated with HIV Resistance
Mechanisms of Antiviral Drug Resistance
Resistance to 2nd Generation NNRTIs
Biomarkers and Complications: Associations and ART Effects
Inflammatory Biomarkers, Immune Activation and ART
e altri ancora.
Inoltre, mi chiedo che cosa mai parleranno in :
HCV Epidemiology and Natural History

Parleranno della storia evolutiva dell'uomo e dell'HCV? L'HCV ai tempi dell'ultima glaciazione?

[Dora]

Non ho avuto molto tempo da dedicare al programma, ma vi segnalo alcune relazioni e alcuni abstract, che spero avranno un po’ più di valore rispetto a quelle schifezze di piante grasse di Uffa, o che mi paiono degni di qualche attenzione.
Premessa: non ci sono Hütter, né la Cannon, né la Collins. Direi che, rispetto all’anno scorso, di novità sul fronte trapianti e staminali non dovrebbero essercene molte.
Direi anche che, rispetto all’anno scorso, la terapia genica fa molto meno la parte del leone. Tuttavia, vi segnalo:

- Nella sezione “Thursday, 10 am-12 n; 6AB Session 42–Oral Abstracts - HIV Persistence, Latency, and Eradication” l’aggiornamento di Sangamo:

11:00 155 Induction of Acquired CCR5 Deficiency with Zinc Finger Nuclease-modified Autologous CD4 T Cells (SB-728-T) Correlates with Increases in CD4 Count and Effects on Viral Load in HIV+ Subjects
C June1, Pablo Tebas*1, D Stein2, R Mitsuyasu3, J Lalezari4, S Wang5, G Lee5, B Levine1, W Tang5, and D Ando5
1Univ of Pennsylvania, Philadelphia, US; 2Albert Einstein Coll of Med, Bronx, NY, US; 3Univ of California, Los Angeles, US; 4Quest Clin Res, San Francisco, CA, US; and 5Sangamo BioSci, Richmond,CA, US

- E poi tutta la sezione di poster “Wednesday, 2-4 pm; Poster Hall Session 86–Poster Abstracts - Novel Gene Therapy Approaches”:

In particolare, a me interessa il poster di Sangamo che fornisce aggiornamenti sulla sperimentazione dell’SB-728-T (Lalezari's version):

433 A Single Infusion of Zinc Finger Nuclease CCR5 Modified Autologous CD4 T Cells (SB-728-T) Increases CD4 Counts and Leads to Decrease in HIV Proviral Load in an Aviremic HIV+ Subject
Jay Lalezari*1, R Mitsuyasu2, S Wang3, G Lee3, M Giedlin3, W Tang3, K Spratt3, R Surosky3, N Dubois-Stringfellow3, and D Ando3
1Quest Clin Res, San Francisco, CA, US; 2Univ of California, Los Angeles, US; and 3Sangamo BioSci, Richmond, CA, US

Un’altra cosa che ho notato è che quest’anno Siliciano e i suoi portano davvero tanti lavori, a conferma di una creatività notevolissima e mi pare anche particolarmente versatile, in linea con quanto abbiamo segnalato nel corso di tutto l’ultimo anno.

******************************************

Ci sono come sempre innumerevoli sessioni dedicate a tutte le questioni infiammatorie, con una particolare attenzione – come lo scorso anno – a tutto quel che riguarda il sistema nervoso centrale e i problemi neurologici.
Tante sessioni dedicate agli ARV già in uso e a quelli in sperimentazione, alle resistenze, alla penetrazione dei farmaci nei diversi comparti anatomici.
Come ha già fatto notare Skydrake, molto spazio è dedicato all’HCV e alle co-infezioni.

******************************************


Passo ora alle moltissime relazioni su reservoir, latenza, eradicazione, che mi pare siano argomento molto più trattato rispetto allo scorso anno, dal punto di vista della quantità di sezioni dedicate, se non della qualità dei lavori portati, che avremo modo di valutare dopo il congresso:


Monday, 9 am-1:30 pm; 6E Session 1–Workshop - Program Committee Workshop for New Investigators and Trainees - 11:00-11:30 am

4 HIV Reservoirs and Cure Research
John Mellors
Univ of Pittsburgh, PA, US

Monday, 2:30-4:30 pm; 613 Session 2–Workshop - Frontiers in Laboratory Science Workshop

8 Laboratory Models for the Study of Latency
A Bosque1, C Novis1, L Martins1, P Ramirez1, M Famiglietti1,2, and Vicente Planelles*1,2
1Univ of Utah, Salt Lake City, US and 2Univ Vita-Salute San Raffaele, Milan, Italy

Wednesday, 4-6 pm; 6D Session 33–Symposium - Pathways toward a Cure: Viral Latency and Reservoirs

Conveners:
Giulia Marchetti, Univ of Milan, Italy
Guido Silvestri, Yerkes Natl Primate ResCtr, Emory Univ, Atlanta, GA, US

106 HIV Latency and Eradication: Clinical Perspectives
Sharon Lewin
Burnet Inst, The Alfred Hosp and Monash Univ, Melbourne, Australia

107 The Role of Non-human Primate Models in the Evaluation of ARV Suppression, Residual Virus, and Viral Eradication Strategies in AIDS Virus Infection
Jeff Lifson
AIDS and Cancer Virus Prgm, SAIC-Frederick, Inc, NCI-Frederick, MD, US

108 Overcoming Pharmacologic Sanctuaries
Courtney Fletcher (spero sia un update rispetto all'importantissimo lavoro portato a St Martin)
Univ of Nebraska Med Ctr, Omaha, US

109 The HIV-1 Eradication Pipeline: Challenges and Opportunities
Daria Hazuda
Merck Res Labs, West Point, PA, US

(sarà la centesima volta che la Hazuda tiene una relazione con questo titolo, non si è ancora stancata?! Oddio, pure la Lewin almeno per il titolo della sua conferenza poteva cercare di ingegnarsi e trovare qualcosa di nuovo …)

Thursday, 1-2 pm; 6E Session 48–Themed Discussion - (see Session 73 on Wednesday for corresponding Poster Abstracts) - Breaking Latency

Discussants:
Una O’Doherty, Univ of Pennsylvania Sch of Med, Philadelphia, US
Jan van Lunzen, Univ Med Ctr, Hamburg-Eppendorf, Germany

365 Binding of RBF-2 Transcription Factor Complexes to Distinct Sites in the HIV-1 Promoter Regulates Viral Transcription
Matthew Dahabieh*1, M Ooms2, T Malcolm1, V Simon2, and I Sadowski1
1Univ of British Columbia, Vancouver, Canada and 2Mt Sinai Sch of Med, New York, NY, US

366 Small Molecule Screening for HIV-1 Reactivation Using in vitro Differentiated Central Memory Cells
Laura Martins*, A Bosque, M Famiglietti, P Ramirez, C Novis, and V Planelles
Univ of Utah, Salt Lake City, US

367 The Effect of the Potent HIV Reactivating Agents Targeting the Epigenetic Environments to Disrupt HIV Latent Cells
SY Park, K-C Kim, D-H Jang, SS Kim, and Byeong-Sun Choi*
Korea Natl Inst of Hlth, Chungbuk, South Korea

368 PMA Disrupts PRC-mediated Gene Silencing to Purge HIV-1 from Latent Cells
Kyung-Chang Kim*1, D-H Jang1, SY Park1, T-Y Roh2, J Park2, SS Kim1, and B-S Choi1
1Korea Natl Inst of Hlth, Chungbuk, South Korea and 2Pohang Univ of Sci and Tech, Gyeongbuk, South Korea


Finalmente arrivano i risultati preliminari sul Disulfiram!

369 Safety and Feasibility of Using Disulfiram to Enhance HIV Transcription among Long-term ARV-treated Adults: Preliminary Results from a Pilot Study
Adam Spivak*1, A Andrade2, R Hoh3, P Bacchetti3, E Eisele2, R Buckheit III2, J Lai2, J Siliciano2, R Siliciano2, and S Deeks3
1Univ of Utah, Salt Lake City, US; 2Johns Hopkins Univ, Baltimore, MD, US; and 3Univ of California, San Francisco, US

370 HDACi LBH589 Stimulates HIV-1 Expression More Potently than Other HDACi in Clinical Use and Disrupts HIV Latency at Clinically Achievable Concentrations
Thomas Rasmussen*1, O Søgaard1, J Melchjorsen1, C Brinkmann III1, L Østergaard1, C Dinarello2, and M Tolstrup1
1Aarhus Univ Hosp, Denmark and 2Univ of Colorado Denver, US

371 HIV-1 Latency Establishment Is Controlled by a Short Promoter Element in the Viral LTR
Frank Wolschendorf*, A Duverger, J Jones, F Wagner, and O Kutsch
Univ of Alabama at Birmingham, US

Ed ora poster e oral abstract su reservoir, latenza, eradicazione:

Thursday, 10 am-12 n; 6AB Session 42–Oral Abstracts – HIV Persistence, Latency, and Eradication
Moderators:

Melissa Churchill, Burnett Inst, Victoria, Australia
Christine Rouzioux, Ctr Hosp Univ Necker, Paris, France

10:00 151 Treatment of Early HIV Infection Reduces Viral Reservoir to Levels Found in Elite Controllers
Maria Buzon*1,2, K Seiss2, A Stone2, F Pereyra2,3, E Rosenberg1, X Yu2, and M Lichterfeld1
1Massachusetts Gen Hosp, Boston, US; 2Ragon Inst of MGH, MIT, and Harvard, Boston, MA, US; and 3Brigham and Womenʼs Hosp, Boston, MA, US

10:15 152 Immediate Antiviral Therapy Restricts Resting CD4+ Infection but Does Not Accelerate the Decay of Latent Infection
N Archin1, N Vaidya2, J Kuruc1, C Gay1, M Kearney3, M Cohen1, J Coffin3, J Eron1, D Margolis1, and Alan Perelson*2
1Univ of North Carolina at Chapel Hill, US; 2Los Alamos Natl Lab, NM, US; and 3HIV Drug Resistance Prgm, NCI-Frederick, MD, US

10:30 153 Elimination of the Latent Reservoir for HIV-1 Requires Induction of CTL Responses
Liang Shan*, K Deng, C Durand, A Rabi, J Blankson, and R Siliciano
Johns Hopkins Univ, Baltimore, MD, US

Questo di Mellors pare la stessa cosa già portata a St Martin:

10:45 154 Plasma Viremia and Cellular HIV-1 DNA Persist Despite Autologous Hematopoietic Stem Cell Transplantation for AIDS-related Lymphoma
Anthony Cillo*1, A Krishnan2, R Mitsuyasu3, D McMahon1, S Li2, J Rossi2, J Zaia2, and J Mellors1
1Univ of Pittsburgh, PA, US; 2City of Hope Natl Med Ctr, Duarte, CA, US; and 3Univ of California, Los Angeles, US

11:00 155 Induction of Acquired CCR5 Deficiency with Zinc Finger Nuclease-modified Autologous CD4 T Cells (SB-728-T) Correlates with Increases in CD4 Count and Effects on Viral Load in HIV+ Subjects
C June1, Pablo Tebas*1, D Stein2, R Mitsuyasu3, J Lalezari4, S Wang5, G Lee5, B Levine1, W Tang5, and D Ando5
1Univ of Pennsylvania, Philadelphia, US; 2Albert Einstein Coll of Med, Bronx, NY, US; 3Univ of California, Los Angeles, US; 4Quest Clin Res, San Francisco, CA, US; and 5Sangamo BioSci, Richmond, CA, US [già segnalato sopra]

11:15 156 Novel Structurally Related Compounds Reactivate Latent HIV-1 in a Bcl-2 Transduced Primary CD4+ T Cell Model without Inducing Global T Cell Activation
Sifei Xing*1, S Bhat1, H Zhang2, J Lopez2, J Margolick2, J Liu1, and R Siliciano1,3
1Johns Hopkins Univ Sch of Med, Baltimore, MD, US; 2Johns Hopkins Univ Sch of Publ Hlth, Baltimore, MD, US; and 3Howard Hughes Med Inst, Baltimore, MD, US [credo sia il lavoro sulle chinoline]


Margolis porta i dati sul SAHA e devo dire che il titolo mi pare assai carino:

11:30 157LB Administration of Vorinostat Disrupts HIV-1 Latency in Patients on ART
N Archin1, A Liberty1, A Kashuba1, S Choudhary1, J Kuruc1, M Hudgens1, M Kearney2, J Eron1, D Hazuda3, and David Margolis*
1 1Univ of North Carolina at Chapel Hill, US; 2HIV Drug Resistance Prgm, NCI-Frederick, MD, US; and 3Merck Res Labs, West Point,PA, US

11:45 158LB Effect of PD-1 Blockade following ART Interruption in SIV+ Macaques
Vijayakumar Velu*1, K Titanji1, R Dyavar Shetty1, HW Lee1, G Freeman2, R Ahmed1, and R Amara1
1Emory Vaccine Ctr, Yerkes Natl Primate Res Ctr, Emory Univ Sch of Med, Atlanta, GA, US and 2Harvard Med Sch, Boston, MA, US


Tuesday, 2-4 pm; Poster Hall Session 70–Poster Abstracts - Viral Persistence on Therapy

345 No Evidence of Evolution in HIV-1+ Patients Receiving Effective cART
Timothy Brennan*1,2,3, J Blankson1, R Siliciano1,4, and C Wilke5
1Johns Hopkins Univ Sch of Med, Baltimore, MD, US; 2NIAID, NIH, Bethesda, MD, US; 3Uniformed Svcs Univ of the Hlth Sci Sch of Med, Bethesda, MD, US; 4Howard Hughes Med Inst, Baltimore, MD, US; and 5Univ of Texas at Austin, US

346 Evolution of HIV-1 Quasi-species and Co-receptor Usage in Cell Reservoirs under Suppressive ART
Stephanie Raymond*1,2,3, A Saliou1, P Delobel1,2,3, M Cazabat3, M Dubois3, R Carcenac3, K Saune1,2,3, P Massip2,3, B Marchou2,3, and J Izopet1,2,3
1INSERM U1043, Toulouse, France; 2Univ Toulouse 3, France; and 3Hosp Univ Toulouse, France

347 Selection of Drug-resistance Mutations at Low Level of HIV-1 Viral Replication in ART-treated Patients
C Delaugerre1, S Gallien1, P Flandre2, D Mathez3, R Amarsy1, S Ferret1, J-M Molina1, and Pierre De Truchis*3
1Hosp St Louis, Paris, France; 2INSERM U943, Univ Pierre and Marie Curie, Paris, France; and 3Hosp Raymond Poincare, Garches, France

348 Low-level Viremia during HAART
Giuliana Cologni*, A Callegaro, C Bernardini, L Soavi, N Iannotti, E Malfatto, D Valenti, G Quinzan, G Gregis, and F Maggiolo
Ospedali Riuniti, Bergamo, Italy

349 Virological Outcome of Patients Displaying Persistent Lowlevel Viremia Comprised between 20 and 50 Copies/mL
Charlotte Charpentier*1, R Landman1, C Laouenan2, V Joly1, G Hamet1, F Damond1, F Brun-Vezinet2, F Mentre2, D Descamps1, and P Yeni1
1Bichat-Claude Bernard Hosp and Paris Diderot Univ, France and 2Bichat-Claude Bernard Hosp and UMR S738 Paris Diderot Univ, France

350 Relationship between Residual Plasma Viremia and HIV Proviral DNA Levels in Heavily Pre-treated Patients
F Cossarini, N Gianotti, L Galli, S Salpietro, C Vinci, E Carini, M Clemanti, S Racca, A Lazzarin, and Antonella Castagna*
San Raffaele Sci Inst, Milan, Italy

Nei lavori che seguono, sono curiosa di capire quante volte verranno (auto)confermati o (auto)smentiti i dati sull’intensificazione portati in tutti gli ultimi congressi:

351 Effect of Maraviroc Intensification on the Decay of HIV-1 DNA in PBMC and Residual Viremia of Recently Infected Patients Initiating Treatment with Raltegravir plus Tenofovir/Emtricitabine: A 48-week Randomized Study
Maria Puertas*1, J Llibre2, M Ballestero1, M Massanella1, M Buzon1, A Esteve3, J Miro4, J Blanco1, B Clotet1,2, J Martinez-Picado1,5, and the MARAVIBOOST Collaborative Group
1AIDS Res Inst, Fndn irsiCaixa, Inst de Recerca en Ciències de la Salut Germans Trias i Pujol, Badalona, Spain; 2Lluita contra la SIDA Fndn, Hosp Univ Germans Trias i Pujol, Badalona, Spain; 3Ctr for Epidemiological Studies on STI and HIV/AIDS of Catalonia, Badalona, Spain; 4Hosp Clin IDIBAPS, Univ of Barcelona, Spain; and 5Catalan Inst for Res and Advanced Studies, Barcelona, Spain

352 Correlation between Infectious HIV-1 Recovery from Resting CD4+ Memory Cells and Residual Plasma Viremia in Patients on ART: Results from ACTG A5173
Rajesh Gandhi*1, R Bosch2, E Aga2, M Bedison3, B Bastow4, J Schmitz5, J Siliciano6, R Siliciano6, J Eron5, J Mellors3, and ACTG A5173 Team
1Ragon Inst of MGH, MIT, and Harvard, Boston, MA, US; 2Harvard Sch of Publ Hlth, Boston, MA, US; 3Univ of Pittsburgh, PA, US; 4Social & Sci Systems, Inc, Silver Spring, MD, US; 5Univ of North Carolina at Chapel Hill, US; and 6Johns Hopkins Univ Sch of Med, Baltimore, MD, US

Questo di Mellors è affine, ma non è propriamente la stessa cosa segnalata sopra. Credo approfondisca una delle questioni lasciate aperte dal successo di Hütter:

353 Impact of Chemotherapy for AIDS-related Lymphoma on Residual Viremia and Cellular HIV-1 DNA in Patients on Suppressive ART
Anthony Cillo*1, S Krishnan2, D McMahon1, R Mitsuyasu3, M Para4, and J Mellors1
1Univ of Pittsburgh, PA, US; 2Harvard Univ, Boston, MA, US; 3Univ of California, Los Angeles, US; and 4Ohio State Univ, Columbus, US


Tuesday, 2-4 pm; Poster Hall Session 71–Poster Abstracts - Viral Replication off Therapy

355 The Effect of ART Intensification on the HIV-1 Latent Reservoir Persists after Discontinuation of the Intensifying Drug: Results of 2 Clinical Trials
Carolina Gutierrez*1, L Diaz2, B Hernandez-Novoa1, A Vallejo1, N Madrid1, M Abad1, A Moreno1, F Dronda1, MA Munoz-Fernandez2, and S Moreno1
1Hosp Ramon y Cajal, Madrid, Spain and 2Hosp Gen Univ Gregorio Marañón, Madrid, Spain

356 Effect of Randomized HAART on Viral Suppression off Therapy in Patients with Acute/Early HIV Infection
Joseph Margolick*1, L Apuzzo1, H Tossonian2, J Singer3, C Fraser4, M Loutfy5, A Rachlis6, P El-Helou7, K Kasper8, and B Conway2
1Johns Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, US; 2Univ of British Columbia, Vancouver, Canada; 3Canadian Inst of Hlth Res Canadian HIV Trials Network, Vancouver; 4Cool Aid Community Hlth Ctr, Victoria, Canada; 5Maple Leaf Med Clin, Toronto, Canada; 6Sunnybrook Hlth Sci Ctr, Toronto, Canada; 7Hamilton Hlth Sci, McMaster Univ Med Ctr, Canada; and 8Hlth Sci Ctr, Winnipeg, Canada

357 Prolonged Control of Replication-competent Dual-tropic HIV-1 following Cessation of HAART
Maria Salgado*1, A Rabi1, K O’Connell1, R Buckheit III1, J Bailey1, A Chaudhry1, J Margolick2, R Siliciano1,3, and J Blankson1
1Johns Hopkins Univ Sch of Med, Baltimore, MD, US; 2Johns Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, US; and 3Howard Hughes Med Inst, Baltimore, MD, US

358 Long-term Control of HIV Reservoir after a 2-Year ART Course at Acute Infection
Alain Lafeuillade*, G Hittinger, V Lambry, G Philip, and C Poggi
Gen Hosp, Toulon, France


Wednesday, 2-4 pm; Poster Hall Session 72–Poster Abstracts - Unconventional Reservoirs

359 HIV Plasma Rebounds in Women at Virologic Failure of ART Reveal Close Genetic Distance to Uterine Cervix and Variants from across Evolutionary Time
Marta Bull*1,2, J McKernan-Mullin2, L Heath1, J Hitti1, K Tapia1, S Holte1,3, J Dragavon1, R Coombs1, J Mullins1, and L Frenkel1,2
1Univ of Washington, Seattle, US; 2Seattle Childrenʼs Res Inst, WA, US; and 3Fred Hutchinson Cancer Res Ctr, Seattle, WA, US

Mi interessa moltissimo il lavoro seguente della Palmer, soprattutto perché – a differenza di quello portato a St Martin il dicembre scorso – questo è solo sulle staminali:

360 Hematopoietic Precursor Cells Isolated from Patients on Long-term Suppressive HIV Therapy Did Not Contain HIV-1 DNA
Lina Josefsson*1,2, S Eriksson1,2, E Sinclair3, M Killian3, W Shao4, B Lewis3, P Bacchetti3, L Loeb3, F Hecht3, and S Palmer1,2
1Karolinska Inst, Solna, Sweden; 2Swedish Inst for Communicable Disease Control, Solna; 3Univ of California, San Francisco, US; and 4Advanced Biomed Computing Ctr, SAIC-Frederick, Inc, NCI-Frederick, MD, US

361 Absence of HIV Evolution in Peripheral Blood- and GALTderived T Cells from Patients on Long-term Suppressive Therapy
L Josefsson1,2, S Eriksson1,2, E Sinclair3, T Ho3, L Epling3, W Shao4, L Loeb3, L Poole3, F Hecht3, and Sarah Palmer*1,2
1Swedish Inst for Communicable Disease Control, Solna; 2Karolinska Inst, Solna, Sweden; 3Univ of California, San Francisco, US; and 4SAICFrederick, Inc, NCI-Frederick, MD, US

362 Comparison of GALT HIV RNA and DNA Levels in HIV+ Controllers, Non-controllers, and HAART-suppressed
Individuals
S Yukl1,2, E Sinclair1, K Harvill1, L Gilman1, R Hoh1, P Hunt1, D Havlir1, J Wong1,2, S Deeks1, and Hiroyu Hatano*1
1Univ of California, San Francisco, US and 2San Francisco VAMC, CA, US

363 HIV Reservoir Size and Immunity in Blood and Sigmoid Colon of Acute HIV+ Thai Subjects following 5- and 3-Drug HAART
Jintanat Ananworanich*1,2,3,4, C Vandergeeten5, A Schuetz3,6, W Ridtitid7, I Sereti8, D Suttichom1, M de Souza3,6, R Dewar9, N Chomont6, J Kim1,3,6, and RV254/SEARCH 010 Study Group
1South East Asia Res Collaboration with Hawaii, Bangkok, Thailand; 2HIVNAT Res Collaboration, Bangkok, Thailand; 3Armed Forces Res Inst of Med Sci, Bangkok, Thailand; 4Thai Red Cross AIDS Res Ctr, Bangkok; 5Vaccine and Gene Therapy Inst, Port St Lucie, FL, US; 6US Military HIV Res Prgm, Rockville, MD; 7Chulalongkorn Univ Faculty of Med, Bangkok, Thailand; 8NIAID, NIH, Bethesda, MD, US; and 9SAICFrederick, Inc, MD, US


Wednesday, 2-4 pm; Poster Hall Session 73–Poster Abstracts - (see Session 48 on Thursday for corresponding Themed Discussion) - Breaking Latency
I poster dal n. 365 al n. 371


Thursday, 2-4 pm; Poster Hall Session 74–Poster Abstracts - HIV Reservoir: Immunologic Markers and Interventions
I poster dal n. 372 al n. 377

[Dora]

Ho pensato, invece di aprire thread nuovi su argomenti che già stiamo trattando, di riportare gli aggiornamenti che arrivano dal CROI nei thread dedicati a quelle ricerche.

Ho già aggiornato

• - K.Collins_Staminali come reservoir, APOBEC3G e altro ancora con il lavoro di Sarah Palmer sul virus nelle staminali e
  
  - Siliciano: perché l’efficacia degli ARV è variabile con l'abstract di Sampah-Siliciano sulla quantificazione gli effetti della combinazione dei diversi ARV nel caso di infezione con HIV wild type oppure resistenti.
  
  - Margolis sul SAHA in Trial su HDACi per eradicazione_Lewin/Margolis vs Clements 2.
  
  - Lalezari e June sull'SB-728-T in [STUDI] Sangamo: CD4 e staminali resi CCR5- mediante ZFN II.
  
  - Siliciano su chinoline, disulfiram e tentativo di eliminazione dei reservoir attraverso anche l'azione citolitica dei linfociti T in [STUDI] Siliciano: tre chinoline per riattivare l’HIV.
  
  - Una domanda a Paula Cannon, a seguito del lavoro di Mellors e Cillo in [STUDI]Cannon_trapianto staminali umane rese CCR5- in topi 2.

Altri aggiornamenti verranno via via segnalati qui.